Novel Extranasal Tear Stimulation: Pivotal Study Results

Novel Extranasal Tear Stimulation: Pivotal Study Results

To evaluate the efficacy and safety of iTEAR, a novel, portable, sonic external neuromodulation device, for the treatment of dry eye disease (DED). This was a multicenter, open-label, single-arm clinical trial that included adult patients with DED with a Schirmer score of ≤10 mm in at least one eye....

Full description

Saved in:
Bibliographic Details
Published in:Translational vision science & technology 2020-11, Vol.9 (12), p.23-23
Main Authors: Ji, Marco H, Moshfeghi, Darius M, Periman, Laura, Kading, David, Matossian, Cynthia, Walman, Gerald, Markham, Scott, Mu, Andy, Jayaram, Ann, Gertner, Michael, Karpecki, Paul, Friedman, Neil J
Format: Article
Language:eng
Subjects:
Adult
Clinical Trials
Double-Blind Method
Dry Eye Syndromes - therapy
Humans
Tears
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the efficacy and safety of iTEAR, a novel, portable, sonic external neuromodulation device, for the treatment of dry eye disease (DED). This was a multicenter, open-label, single-arm clinical trial that included adult patients with DED with a Schirmer score of ≤10 mm in at least one eye. Enrolled subjects were instructed to apply the study device at least twice per day for 30 seconds bilaterally to the external nasal nerve. After the initial baseline visit, patients were followed up at days 3, 14, 30, 90, and 180. The primary efficacy endpoint was the Schirmer index (change from unstimulated to stimulated tear production as measured by the Schirmer test) at day 30. The major secondary endpoint was the change in symptoms of DED at day 30 evaluated using the Ocular Surface Disease Index (OSDI). A total of 101 subjects evaluated at day 30 had a mean Schirmer index of 9.4 mm (95% confidence interval [CI], 7.4-11.3), and the baseline OSDI improved by an average of 14.4 (95% CI, 11.1-17.7). Both endpoints were highly statistically and clinically significant at all time points. There were two mild unanticipated adverse events definitely related to the device. The safety and efficacy of the iTEAR device observed in this study support its indication for treating DED. Neurostimulation has the potential to improve signs and symptoms of DED.
ISSN:2164-2591
2164-2591